NCT06116526View on ClinicalTrials.gov

Dupilumab De-escalation in Pediatric Atopic Dermatitis

PHASE4RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

April 1, 2026

Study Completion Date

April 30, 2027

Conditions
Atopic Dermatitis
Interventions
DRUG

Dupilumab - Discontinuation

Drug injections are discontinued.

DRUG

Dupilumab - Dose Reduction

The drug is given as a subcutaneous injection.

DRUG

Dupilumab - Standard Dose

The drug is given as a subcutaneous injection.

Trial Locations (1)

21210

RECRUITING

Johns Hopkins Univerisity, Baltimore

All Listed Sponsors
collaborator

Doris Duke Charitable Foundation

OTHER

lead

Johns Hopkins University

OTHER